ReportsSuccessful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis☆,☆☆,★
Section snippets
Patients
Nineteen adult patients (12 male, 7 female) with moderate to severe plaque-type psoriasis were sequentially enrolled into our study, which was approved by the Rockefeller University Hospital and University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School Institutional Review Boards. Enrollment excluded patients with guttate, erythrodermic, and pustular psoriasis. Of the 19, 17 had previously been treated with two or more systemic therapies, including phototherapy (UVB
Results
Eighteen of 19 patients completed the entire study. There were no significant adverse events in any patient. All routine laboratory values remained within normal limits during and for 2 months after infusions. As a safety measure, we calculated the total number of T cells during the course of therapy. The average absolute T-cell count before treatment was 1200. This remained unchanged until week 12 when there was a slight increase to 1674 (normal range, ~420-5000).
Our first objective was to
Discussion
Psoriasis is now recognized as disease that is induced and sustained by skin-infiltrating T-lymphocytes.11 Lesion-infiltrating lymphocytes include intraepidermal CD8+ T cells with the phenotype of cytotoxic effectors7 and CD4+ T helper type 1 cells that are capable of producing high levels of interferon gamma, tumor necrosis factor α, and other “effector” cytokines.6 Both of these T-cell subtypes express high levels of CD25 in psoriatic skin lesions compared with T cells that circulate.7 Given
References (34)
- et al.
The majority of epidermal T cells in psoriasis vulgaris lesions produce type 1 cytokines IFN-γ, IL-2 and TNF-α, defining TC1 CTL and TH1 effector populations: a type 1 differentiation bias is also measured in circulating T cells in psoriatic patients
J Invest Dermatol
(1999) - et al.
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor
Blood
(1994) - et al.
FK506 in the treatment of inflammatory skin disease: promises and perspectives
Immun Today
(1996) - et al.
Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4
J Autoimmun
(1998) Selectins and their ligands: current concepts and controversies
Blood
(1996)Regulation of the human interleukin-2/inter-leukin-2 receptor system: a role for immunosuppression
Proc Soc Exp Biol Med
(1994)- et al.
A humanized antibody that binds to the interleukin 2 receptor
Proc Natl Acad Sci U S A
(1989) - et al.
A monoclonal antibody, 7G7B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-TAC
Hybridoma
(1985) - et al.
Response of psoriasis to a lymphocyte-selective toxin (DAB 389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
Nature Med
(1995) - et al.
Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques
J Exp Med
(1986)
CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry
J Autoimmun
Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
N Engl J Med
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial
Proc Natl Acad Sci U S A
Pathogenic interactions of keratinocytes and T lymphocytes in psoriasis
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
J Clin Invest
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
Nature
Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection
Proc Natl Acad Sci U S A
Cited by (0)
- ☆
Supported in part by a General Clinical Research Center Grant (M01-RR00102) from the National Center for Research Resources at the National Institutes of Health (NIH); by NIH grant AI39214; and by a grant from Hoffmann-LaRoche, Inc.
- ☆☆
Reprint requests: James G. Krueger, MD, PhD, Laboratory Head, Laboratory for Investigative Dermatology, The Rockefeller University, 1230 York Ave, Box 178, New York, NY 10021-6399. E-mail: [email protected].
- ★
J Am Acad Dermatol 2000;43:448–58.